Articles Tagged With: piperacillin-tazobactam
-
Comparing the Safety of Cefepime to Piperacillin-Tazobactam in Adults with Acute Infections
There was no significant difference in the incidence of acute kidney injury in patients given piperacillin-tazobactam vs. cefepime for sepsis.
-
Comparing the Safety of Cefepime and Piperacillin-Tazobactam: The ACORN Trial
Qian and colleagues conducted a pragmatic, open-label, randomized clinical trial to determine whether the empiric use of piperacillin-tazobactam or cefepime affects the risk of acute kidney injury (AKI) or neurological dysfunction in patients hospitalized for sepsis. The study showed no significant difference in the incidence of AKI between groups, but rates of neurological dysfunction were slightly higher in patients treated with cefepime.
-
Meropenem vs. Piperacillin-tazobactam for Bacteremia Due to ESBL-Producers: The MERINO Trial
In an open-label, randomized, noninferiority trial evaluating the efficacy of piperacillin-tazobactam vs. meropenem for definitive therapy in treating bacteremia caused by extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae, piperacillin-tazobactam therapy did not result in noninferior 30-day, all-cause mortality compared to meropenem. Investigators stopped the trial early due to futility.
-
Meropenem-vaborbactam
Meropenem-vaborbactam (Vabomere) is the latest β-lactam/β-lactamase inhibitor (BLI), approved by the FDA in August 2017 for treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by susceptible Escherichia coli, Klebsiella pneumoniae, and Enterobacter cloacae species complex in adults older than 18 years of age.
-
Vancomycin Combined with Piperacillin-Tazobactam Increases the Risk for Acute Kidney Injury
A retrospective cohort study found an increased risk of acute kidney injury for patients who received vancomycin in combination with piperacillin-tazobactam compared to those who received vancomycin plus cefepime (hazard ratio = 4.27; 95% confidence interval, 2.73-6.68).